Herantis Pharma PLC · OMXHEX:HRTIS

Herantis Pharma — TreatER webinar 2020

18 slides from Herantis Pharma's conference presentation, Nov 18, 2020

  1. Slide 1: Neurotrophic factors in clinical trials – A brief look to the recent past, present and years to come

    Neurotrophic factors in clinical trials – A brief look to the recent past, present and years to come Mart Saarma Institute of Biotechnology, HiLIFE, University of Helsinki TreatER webinar 18 Nov 2020 Wednesday 18th November, 2020 Mart Saarma

  2. Slide 2: Parkinson's disease (PD): more than 10 million patients and no cure

    Parkinson’s disease (PD): more than 10 million patients and no cure n Progressive neurodegenerative movement disorder ¨ Loss of dopamine neurons in the nigrostriatal pathway n Major symptoms: slowness of movement, resting tremor, rigidity and postural instability, but also non-motor symptoms n Motor

  3. Slide 3: Neurodegeneration in PD and current symptomatic treatments

    Neurodegeneration in PD and current symptomatic treatments n Current therapies (e.g. L- n DA neurons lose synapses dopa+carbidopa+entacapone or dopamine agonists) are symptomatic and do not arrest or n DA neuronal axons attenuate the progression of the degenerate disease n Future therapies should in

  4. Slide 4: Why and how dopamine neurons degenerate and die?

    Why and how dopamine neurons degenerate and die? n Postmitotic cells with very modest or no neurogenesis in mammals n Have extensive network of neurites that is demanding for energy and intracellular trafficking (500,000 dopamine release spots per neuron!) n Produce massive amounts of dopamine that

  5. Slide 5: Neurotrophic factors can keep neurons alive and protect them

    Neurotrophic factors can keep neurons alive and protect them n Promote neuronal survival and control the number of neurons in the nervous system n Stimulate neurite outgrowth and axonal regeneration n Protect neurons from toxins and injury n Regulate synaptic plasticity n Nerve growth factor (NGF) w

  6. Slide 6: The Nobel Prize in Physiology or Medicine for Levi-Montalcini and Cohen in 1986

    The Nobel Prize in Physiology or Medicine for Levi-Montalcini and Cohen in 1986 "for their discoveries of growth factors" Stanley Cohen Rita Levi-Montalcini Victor Hamburger 1922-2020 1909-2012 1900-2001 Mart Saarma

  7. Slide 7: GDNF family ligands GDNF and NRTN activate GFRα-RET receptor complexes

    GDNF family ligands GDNF and NRTN activate GFRα-RET receptor complexes promoting survival and regenerating axons of dopamine neurons in neurotoxin animal models of PD Trupp et al. Nature, 1996; Durbec et al. Nature, 1996 Airaksinen & Saarma Nature Rev. Neurosci., 2002; Andressoo & Saarma Curr. Opin.

  8. Slide 8: GDNF signalling

    GDNF signalling GDNF binds first to the co-receptor GFRα1 and then the complex binds to and activates RET MAPK/ERK -> pMAPK/pERK PI3K/AKT -> pPI3K/pAKT Src-> pSrc Signalling P P GDNF and NRTN activate via RET transcription factors inducing long-lasting effects Leppänen et al. EMBO J., 2003; Parkash

  9. Slide 9: Intracranially injected GDNF & NRTN can protect and repair DA neurons in animal models of PD

    Intracranially injected GDNF & NRTN can protect and repair DA neurons in moderate neurotoxin animal models of PD GDNF and NRTN can protect and repair DA neurons in neurotoxin-induced animal models of PD GDNF and NRTN are basic proteins and diffuse poorly in mammalian brain GDNF has no effects on AAV

  10. Slide 10: GDNF and NRTN in phase I-II clinical trials for Parkinson's disease

    GDNF and NRTN in phase I-II clinical trials for Parkinson’s disease n There have been 3 phase II clinical trials with GDNF protein and the outcome is: a) no clear clinical benefit in two first trials b) promising results with GDNF in the third trial n Two phase II clinical trials with NRTN gene ther

  11. Slide 11: Clinical trial I: Intraventricular infusion of GDNF (Nutt et al. 2003)

    Clinical trial I: Intraventricular infusion of GDNF (Nutt et al. 2003) 50 patients; placebo (n=12), various monthly doses of GDNF (25 to 4 000 micrograms) n randomized, double-blind (8 months), open-label up to 20 months n no improvement of UPDRS motor score n adverse events common: e.g., paresthesi

  12. Slide 12: Clinical trial III: intermittent GDNF protein delivery

    Clinical trial III: Dr. S. Gill, Dr. A. Whone and Medgenesis Ltd. used intermittent GDNF protein delivery Mart Saarma

  13. Slide 13: Clinical trial III: Dr. S. Gill, Dr. A. Whone and Medgenesis Ltd.

    Clinical trial III: Dr. S. Gill, Dr. A. Whone and Medgenesis Ltd. With all patients pooled UPDRS score did not show significant differences between the groups either A post hoc analysis found nine (43%) patients in the active group but no placebo patients with a large clinically important motor impro

  14. Slide 14: Dopamine neurons degenerate and die in the midbrain of PD patients

    Dopamine neurons degenerate and die in the midbrain of PD patients Starting from 4-6 years after diagnosis PD patents have very little TH-positive fibres of dopamine neurons in the caudate putamen In animal models neurotrophic factors do not work when more than 80% of the fibres have been lost Kordo

  15. Slide 15: GDNF can slow down neurodegeneration in PD patients – what can we do better?

    GDNF can slow down neurodegeneration in PD patients – first time in the treatment of a chronic neurological disease? What can we do better? Treatment should be started as soon as possible after diagnosis – ethical considerations connected to invasive surgery do not allow to treat early stage patient

  16. Slide 16: CDNF discovery - unique sequence, 3D structure and mode of action

    CDNF discovery - has unique sequence, 3D structure, mode of action and forms with MANF a novel group of unconventional neurotrophic factors urorotophic factor Päivi Lindholm • MANF and CDNF in vertebrates; single CDNF/MANF homolog in invertebrates (50% homology). • No sequence homology with other pr

  17. Slide 17: CDNF protects and rescues dopamine neurons in animal models of Parkinson's disease

    CDNF protects and rescues dopamine neurons in animal models of Parkinson’s disease and also affects some non-motor symptoms We formed a biotech company Herantis Pharma Ltd. that has started to develop CDNF-based drugs Mart Saarma

  18. Slide 18: Thank you for your attention!

    Thank you for your attention! Kaari Saarma photo Mart Saarma

Herantis Pharma — TreatER webinar 2020 on 6ix